Literature DB >> 7548329

Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea.

G Castello1, R Lerza, A Cerruti, D Cavallini, G Bogliolo, I Pannacciulli.   

Abstract

The in vivo effects of hydroxyurea (HU) on circulating erythroid (BFU-E) and granulocyte-macrophage progenitors (CFU-GM) in patients with polycythemia vera (PV) have been evaluated. HU induced a strong decrease of both BFU-E and CFU-GM in the first month of treatment. During the following 4 months of treatment the level of circulating progenitors remained at very low values, until the end of the period of observation. HU activity involved both erythroid and myeloid committed progenitors and both erythropoietin-stimulated (normal) and endogenous (derived from the abnormal PV clone) BFU-E.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7548329     DOI： 10.1007/bf01702646

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  10 in total

1.  Diagnosis and classification of the polycythemias.

Authors:  N I Berlin
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

2.  Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A.

Authors:  N N Iscove; F Sieber; K H Winterhalter
Journal:  J Cell Physiol       Date:  1974-04       Impact factor: 6.384

3.  A new treatment for polycythemia vera: recombinant interferon alfa.

Authors:  R T Silver
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

4.  Endogenous erythroid colony formation by peripheral blood mononuclear cells from patients with myelofibrosis and polycythemia vera.

Authors:  J D Lutton; R D Levere
Journal:  Acta Haematol       Date:  1979       Impact factor: 2.195

5.  Effects of S-phase-specific agents on granulocyte-macrophage and erythroid progenitor cells obtained from normal individuals and from patients with chronic myelogenous leukemia.

Authors:  K Kubota; H D Preisler; C Costanzo
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

6.  Polycythemia vera. The in vitro response of normal and abnormal stem cell lines to erythropoietin.

Authors:  J F Prchal; J W Adamson; S Murphy; L Steinmann; P J Fialkow
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

7.  Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K B McCredie; M J Keating; J Trujillo; J Gutterman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

8.  The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera.

Authors:  G Castello; R Lerza; A Cerruti; D Cavallini; G Bogliolo; I Pannacciulli
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

9.  Treatment of polycythemia vera with hydroxyurea.

Authors:  P B Donovan; M E Kaplan; J D Goldberg; I Tatarsky; Y Najean; E B Silberstein; W H Knospe; J Laszlo; K Mack; P D Berk
Journal:  Am J Hematol       Date:  1984       Impact factor: 10.047

10.  Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin.

Authors:  E D Zanjani; J D Lutton; R Hoffman; L R Wasserman
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.